If only US health care could be more like the Patriots (or even the Red Sox) and less like the Yankees
David E. Williams
Health business blog
I don’t much care for sports analogies but today I can’t help myself.
We’ll never get to the ideal state in health care, but I’d be more than satisfied with something like the 2007 Boston Red Sox: spending the second most of any team and achieving the best results.
Well, we can dream.
Health Business Blog is a regular contributor to BioHealth Investor
_________________
Health business blog
I don’t much care for sports analogies but today I can’t help myself.
The US health care system is like the New York Yankees: spending more money than anyone else, under-performing its peers that spend less than half of what it spends, and constantly looking to reform itself with expensive new programs.
The ideal system would be like the New England Patriots: achieving unprecedented superiority (the headline after yesterday’s 52-7 victory over the Redskins: “Washington slapped here“) despite spending roughly the same amount as everyone else thanks to the salary cap, emphasizing teamwork over individual performance, and constantly innovating. It helps to have a Wesleyan grad at the helm.
We’ll never get to the ideal state in health care, but I’d be more than satisfied with something like the 2007 Boston Red Sox: spending the second most of any team and achieving the best results.
Well, we can dream.
Health Business Blog is a regular contributor to BioHealth Investor
_________________
2 Comments:
Attention Mr.Ayoub, Your article of the top biotech stocks has left me puzzled.Unless you mean that individually that they went up the most that day. If so fine. Otherwise,
if NSTK had double the earnings loss and is only in phase 2 (early stages)
the likelihood of any approvals maybe is in 2009. Since it has been reported that hedge funds are being investigated for manipulation, and P&G has deferred any payments as of last Dec.2006 until maybe 6 months from now, how do you personally post on this site that it is a top 5 biotech for all to view. Isn't a bit misleading to investors?
How about the tremendous efforts of one Mr.Cramer for touting this company above and beyond the NORM for past 10 months. Including video's on nstk & special guest appearances by the CEO on his show. He single handidly has become the poster boy for this stock and should be head of Public Relations. I mean really, doesn't the SEC look at his?
Post a Comment
Subscribe to Post Comments [Atom]
<< Home